ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2025
Antibacterial activity of alginate-casein nanocapsules containing allicin against multidrug-resistant Pseudomonas aeruginosa.
Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Insights and Antibiotic Resistance ofFood science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa (P. aeruginosa) represents a critical global health challenge due to its escalating antibiotic resistance and its formidable ability to form protective biofilms, necessitating the urgent development of novel therapeutic strategies. This research explores the potential of allicin, a natural antibacterial compound, encapsulated within alginate-casein (ACAN) nanoparticles as a promising approach to combat multidrug-resistant (MDR) P. aeruginosa proliferation and biofilm formation. The ACAN nanoparticles were comprehensively characterized for their morphological traits using FESEM, DLS, and FTIR, confirming successful allicin encapsulation and enhanced stability. Notably, the ACAN formulation demonstrated significantly improved antibacterial efficacy and a profound ability to inhibit biofilm growth. Specifically, ACAN nanoparticles achieved up to 77% inhibition of P. aeruginosa biofilm growth, a statistically significant improvement compared to free allicin (e.g., ~ 28% inhibition). Furthermore, the study investigated the impact of ACAN on key biofilm-related genes, revealing a marked downregulation of pslG (involved in exopolysaccharide production) and lasI (critical for quorum sensing and biofilm maturation). These findings collectively highlight that encapsulating allicin within alginate-casein nanoparticles not only enhances its stability and delivery but also significantly boosts its efficacy against the persistent biofilm-forming capabilities of MDR P. aeruginosa. This novel ACAN platform thus presents a compelling and promising therapeutic strategy for addressing challenging bacterial infections.
Indexed as
Identifiers
40719811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.